Clinical Data ASCO26: In vivo oncology approaches continue to show promise Pharmaceutical TechnologyLilly's $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.OncologyRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) Pharmaceutical Technology Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to comeNext: ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
